Drug Trial Radar · NCT05975021
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Actual
Start
Jun 1, 2024
Primary completion
Jul 28, 2025
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Windtree TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current trial aims to assess the effect of istaroxime in patients with SCAI Stage C Cardiogenic Shock (CS). These patients look unwell, frequently with a sudden change in mental status, mottled and cool extremities, and delayed capillary refill, as well as signs of congestion and relative low blood pressure and signs of hypoperfusion (reduced oxygen to organs) which frequently require support with rescue therapies including inotropes, vasopressors, or mechanical devices. Windtree Therapeutics, Inc. has been studying istaroxime, which has the potential to treat patients in this condition without some of the disadvantages of existing therapies being used to treat patients with acute heart failure and CS. Participants enrolled in this trial will receive standard of care (SoC) therapy for heart failure and CS. Additionally, half of the participants will be randomly chosen to receive istaroxime. Istaroxime has the potential to increase blood pressure and improve cardiac function.
Conditions
- Cardiogenic Shock
Interventions
IstaroximeDrug
IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.
PlaceboDrug
IV infusion via a syringe pump. Total duration 48 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SBP AUC 0-6Time frame: Start of infusion to 6 hours
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
Tufts Medical Center
Boston, Massachusetts
Oregon Health and Sciences University
Portland, Oregon
Sanatorio Güemes
Capital Federal, Buenos Aires, Argentina
Sanatorio De la Trinidad Palermo
Capital Federal, Buenos Aires, Argentina
Instituto Cardiovascular de Rosario
Rosario, Sante Fe, Argentina
Hospital Privado de Rosario
Rosario, Sante Fe, Argentina
Kaplan Medical Center
Rehovot, Israel
Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
ASST degli Spedali Civili di Brescia
Brescia, Italy
IRCCS San Raffaele Scientific Institute
Milan, Italy
University of Turin, Città della Salute e della Scienza
Turin, Italy
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, Poland
Uniwersytecki Szpital Kliniczny w Opolu
Opole, Poland
Uniwersytecki Szpital Kliniczny, Instytut Chorob Serca
Wroclaw, Poland
4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.